| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Strategic Planning > Don't Let Your Business Become a Wounded Dog |
|
E-Folder - Don't Let Your Business Become a Wounded Dog
In business, as in life, adversity is a recurrent and inescapable event. The clich?: “Into every life a little rain must fall” is true no matter one’s education or level of success According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product . The key difference between the businesses that close never to reopen again and those that thrive through their adversity is resilience. Everyone knows that there is nothing more d ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in angerous than a wounded animal. An injured animal seeks to protect itself by striking out against all who approach. However dogs are unique in that they will invariably find one per lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. son with whom to bond. This difference is inexplicable, but predictable. They may not even choose their owner or master. Nonetheless wounded dogs will drag themselves to the feet o here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe f their chosen protector, nuzzling and begging for help. These wounded dogs know that they are no longer capable of caring for themselves and that one more adversity befalls them and d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro they will die. Businesses become wounded dogs when they fail to ensure that an adversity does not evolve into a disaster. In two decades of disaster field work and consulting to com ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc panies large and small I have seen and helped more than my share of wounded dogs. In all cases it did not matter whether the adversity came from outside the company such as a hurrica easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ne, earthquake or terrorist attack or if the adversity came from within; poor product design, marketing mishaps, financial missteps, or employee sabotage. The result is always the sa nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically me. Some critical business pathway collapses resulting in a business disaster. Observers both inside and outside the wounded business say that the disaster was “inevitable.” In the and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ disaster field office, we know that no disaster is “inevitable.” Disaster is a simple equation no more different than profit and loss. Disaster = Needs > Resources. The most basic ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi analogy is the financial disaster of “want” exceeding “wallet,” but this same equation holds true in all other critical areas of business. Conversely, resilience, the ability to cope ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a with adversity and stave off disaster, is also represented by the simple equation: Resilience = Resources > Needs. Again the analogy is the financial resilience of “wallet” exceedin dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod g “wants.” Now if this were the end of the story, one short speech, one short consultation, one small article in the Wall Street Journal and I could end all business disasters. The cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin trick here is being able to identify what resources to have in abundance since nobody can have resources for all contingencies. Resource identification is based not on determining ev tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ery possible adversity that can face a business. This is an incalculably high number and bounded only by the imagination not only of those that run the business but all of those who t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ay wish it ill. Rather, resource determination is based on an evaluation of the processes and pathways unique to each business. It requires the identification of “choke points,” tho ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust se critical pathways that, if narrowed or destroyed, will choke off the life of the business. It is these critical steps for which resources are amassed. The goal is to ensure that n y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products o choke point becomes so narrow as to strangle the life of the business. This ensures resilience. Some have adapted well through the application of the lessons I learned in the disa . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ster field office. Others have failed to learn these lessons resulting in business disaster. In a few cases, the businesses stumbled upon their resilience. In others they were guide elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip d to it. But in all cases it was the identification of choke points and the allocation of resources that ensured that a business remained in business and did not become a wounded dog tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:3 Reasons Why Your Business Should Not Be You The Pros And Cons Of Outsourcing Marketing Function For Small Business Owners Business 101 - Strategy for Setting Up Your Business
|